chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I had a metal taste about 20 minutes after my shot similar to what I had back in March 2020.  This lasted a couple hours. The nurse said she has seen this in patients who had previous infection. Note-  I took a Binax rapid test the night before my test and it was negative. I also had a sensation of chest tightness and lip swelling and a headache. The headache continued Saturday and my lip still has a slight sensation today Sunday morning and I am still tired.  I did have soreness in my chest under my right breast and soreness where I got the shot -- right arm. It is believed I was previously infected back in March 2020 when they were not testing and was home from work for 14 days. I am O Positive blood type. Do I really need a second shot? I do not think I need one.
Left arm where vaccine administered became extremely painful, swollen to almost double in size. Ran temperature 101 degrees. Called 911 at 12:30 AM and ER. Spoke to nurse. Fri: left arm (blood drawn for test) became swollen and red. Being treated with antibiotics, 10 days, Cephalexin 500mg.
Both eyes started twitching that day a bit after 5pm.  They still continue to twitch every so often.
Tested positive for covid 19; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (Tested positive for covid 19) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032b21a) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Apr-2021, the patient experienced SARS-COV-2 TEST POSITIVE (Tested positive for covid 19). At the time of the report, SARS-COV-2 TEST POSITIVE (Tested positive for covid 19) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Apr-2021, COVID-19: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported Treatment medication was not provided
At the time of injection, I started to go numb everywhere in my body, feeling a tingling sensation that lasted 20-25 minutes. It was difficult to move my extremeties.  The day after the vaccine, I had chills, body aches, a headache, and was very lethargic.
temp. excursion, Max/low temperature reached: Exposed to temperature of 11C with no reported adverse event; IPOL has been administered to a patient with no reported adverse event; Initial information received on 11-Sep-2023 regarding an unsolicited valid non-serious case received from a Nurse.  This case involves an unknown age and unknown gender patient where temp. excursion, max/low temperature reached: exposed to temperature of 11c with no reported adverse event and IPV (VERO) [IPOL] has been administered to a patient with no reported adverse event.  The patient's past medical history, medical treatment(s), concomitant medication(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect IPV (VERO) Suspension for injection (lot- W1A191M and expiration date- 16-Feb-2025) via unknown route in unknown administration site (dose, strength: not provided) for immunization (product storage error) and (poor quality product administered).  Action taken- Not applicable.  At time of reporting, the outcome was Unknown for the event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Mild pain at injection site; Itchiness at injection site; This is a spontaneous report from a contactable consumer via Pfizer Sales Representative. A contactable consumer of an unspecified age and gender received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, lot number and expiry date were not reported) via an unspecified route of administration on an unspecified date as SINGLE dose for covid-19 immunization. Historical vaccine included received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, lot number and expiry date were not reported) via an unspecified route of administration on an unspecified date as SINGLE dose for covid-19 immunization. The patient's medical history and concomitant medications were not reported. Patient was a neighbour of the reporter, who developed mild pain and itchiness at injection site after second dose of the vaccine. The outcome of the events was unknown.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
Patient fainted at the front of the store approximately 15 minutes after receiving  her vaccine. I did not witness the faint but was told that she fell to the ground and within seconds was awake. When I reached the front she was sitting upright and stated that she felt ok. She had been given something to drink and was given an ice pack. Patient's mother stated that she is prone to fainting and has fainted before after having blood drawn.
2 weeks after vaccine the child developed approximately 30 maculopapular spots (2 with vesicles) evenly distributed over her body. She was itchy but had no fever. No other siblings developed any similar dermatitis at the time.
I got the first vaccine and then got Shingles; Nerve damage is incurable, had the Shindrix vaccines but no help; This case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced shingles and nerve damage. On an unknown date, the outcome of the shingles was unknown and the outcome of the nerve damage was not recovered/not resolved.   It was unknown if the reporter considered the shingles and nerve damage to be related to Shingrix.     Additional Information: GSK Receipt Date: 14-FEB-2023 Reporter's Comments: The case was received from the patient via interactive digital media. The patient got the first vaccine and then got shingles.  The patient stated that the nerve damage was incurable and had the Shingrix vaccines since. No help but possible a preventative against future attack. Additional Supportive Information: The follow-up could not be possible as no contact details were available.; Sender's Comments:  US-GSK-US2023AMR025271:Same reporter (Deletion case)
the patient who is unsure how many doses of Gardasil she received as a child/ She is interested in receiving the vaccine/ may have had alternate dosing of either GARDASIL 4 or GARDASIL 9; the patient who is unsure how many doses of Gardasil she received as a child/ She is interested in receiving the vaccine/ may have had alternate dosing of either GARDASIL 4 or GARDASIL 9; the patient who is unsure how many doses of Gardasil she received as a child/ She is interested in receiving the vaccine/ may have had alternate dosing of either GARDASIL 4 or GARDASIL 9; No adverse effects reported; This spontaneous report was received from a physician, regarding a female patient of unknown age. The patient's pertinent medical history, concurrent conditions, concomitant medications and previous drug reactions/allergies were not reported.  On an unknown date, (reported as "when she was a child"), the patient was vaccinated with either human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) or with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (strength, dose, vaccination scheme, route of administration, lot number or expiration date were not reported) as prophylaxis. The reporter mentioned that the patient was unsure about how many doses she received as a child, and it was reported that "she was interested in receiving the vaccine" (circumstance or information capable of leading to medication error, interchange of vaccine products and wrong product administered). No additional adverse events were reported.
Patient complained of redness, warm to touch and itch on left arm below injection site about 2-3 inches below on the day after injection.
Patient received a full series of Moderna and came in for a booster dose. The affiliated physician hotline was called to confirm before proceeding. The hotline said it was okay to give the patient a modern booster. After the patient was vaccinated, the hotline requested a copy of the patient's POV. They realized she received a spiked vac Moderna series, which is different from Moderna. Therefore, the patient should have received a Pfizer booster.
Within 5-7 days of second series fo Twinix Hep A and Hep B vaccination suffered from joint pain in most joints and particularly in hands. In addition, had trouble thinking clearly and suffered from malaise, depression, and inability to perform work. Reported to physician but no tests showed anything abnormal.  Continue to suffer from joint pain in hands sometimes severely if I use my hands a lot.
Exquisitely tender right sided epitrochlear, axillary, and supraclavicular lymphadenopathy. Began about 16 -20 hours after receiving vaccination.  Still present at 36 post vaccination, but seems to be improving.
This spontaneous report was received from a pharmacist, concerning a patient of an unknown age and gender. There were no concurrent conditions, medical history, drug reactions or allergies or concomitant medications reported. On an unspecified date in 2009, the patient was vaccinated intramuscularly with the first dose of VAQTA (dose, frequency, route, lot # and expiration date not reported) for prophylaxis. On 07-FEB-2017, the patient was vaccinated intramuscularly with an expired dose of VAQTA (dose and frequency not reported; lot # L031196 and expiration date: 05-FEB-2017) for prophylaxis. Temperature: "36 to 46 F". There was no previous temperature storage excursion occurred for the vaccine per the reporter. No adverse effects were reported. No product quality complaint was involved (PQC). This is one of two reports received from the same source. Additional information has been requested.; Sender's Comments: US-009507513-1702USA003657:
Within 3 minutes of receiving the vaccine, I felt a fluid like sensation trickle down my right bicep. I think proceeded to feel tachycardia, dizziness, lightheaded, and was hypertensive. My chest appearance was red and blotchy as well as my face. I was monitored in the ED for 2 hours. My vitals stabilized and the redness dissipated. I continued to feel a bit anxious and a headache. I was told to go home, take Benadryl as needed, and to follow up with an allergist.
Gait disturbance, weakness 10/15/10. Increased weakness & falls. Admitted to hospital 10/22/10 testing. Diagnosed with Guillian Barre on 11/1/10, started IVIG treatments 11/1/10. Currently in-pt at hospital.
Narrative:  Unsure of narrative or history. Patient presented to clinic to establish care and simply noted "anaphylaxis" with Pfizer COVID-19 vaccine. Her physician recommended against the second vaccine.
terrible pain in the left side of the back , she was in so much pain.; terrible pain in the back of the shoulder; This spontaneous case was reported by a patient and describes the occurrence of BACK PAIN (terrible pain in the left side of the back , she was in so much pain.) and ARTHRALGIA (terrible pain in the back of the shoulder) in a 68-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 059F22A) for COVID-19 vaccination.     It was unknown if patient received any other vaccines within 1 month prior to Moderna COVID-19 vaccine. It was unknown if patient had ever tested or diagnosed for COVID-19. It was unknown if patient had allergy. It was unknown if patient had acute and Chronic illnesses at the time of vaccination.  Concurrent medical conditions included Blood cholesterol abnormal. Concomitant products included EZETIMIBE for Blood cholesterol abnormal, VITAMINS NOS for an unknown indication.    On 22-Oct-2022, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 23-Oct-2022, the patient experienced BACK PAIN (terrible pain in the left side of the back , she was in so much pain.) and ARTHRALGIA (terrible pain in the back of the shoulder). At the time of the report, BACK PAIN (terrible pain in the left side of the back , she was in so much pain.) and ARTHRALGIA (terrible pain in the back of the shoulder) had not resolved.            Reported that patient received first dose of Moderna COVID-19 Vaccine on 21Jan2021, second dose on 18Feb2021, first booster on 8Aug2021, and last booster on 22Oct2022 with Lot number: 030L20A, 015M20A, 059F22A, 059F22A and Expiration date: unknown. It was unknown if AE cause patient to seek medical care (office visit, Urgent care, ER, hospitalized). It was unknown if patient experienced a similar event in the past. It was unknown if any treatment was given for her symptoms.   This case was linked to MOD-2022-664514 (Patient Link).
The patient experienced swelling, redness and nodule at the injection site; The patient experienced swelling, redness and nodule at the injection site; The patient experienced swelling, redness and nodule at the injection site; hand pain; This spontaneous report was received from a pharmacist and refers to a 53 year old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not provided.  On 21-AUG-2019, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) subcutaneous for prophylaxis,  lot # S005248, expiration date on 20-FEB-2021, (strength, dosage and frequency were not provided).  In September 2019 (reported as "two to three weeks after adminstration"), the patient experienced swelling, redness, and a nodule at the injection site was well hand pain. The patient did not seek medical attention and there was not treatment given for the adverse events.  The patient had recovered from injection site swelling, pain in extremity, injection site nodule and injection site erythema on an unspecified date in 2019.  The reporter did not provide causality assessment between the events and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II).
11oct89 pt vax hepta B 3rd dose. pt noted area of atrophy below inject site between L-elbow& shoulder. devel. muscle weakness which cause pt to drop objects.24jan90 indentation persisted. physician felt it fatty tissue atrophy.
Pain in left arm; by 2 PM left arm could not be moved; by 4 PM extreme pain; swelling; treated swelling with ice packs; pain with Tylenol; by 11/27/13 most but not all swelling has subsided; still residual pain with some movements of left arm.
several minutes after injection on deltoid developed large wheal, vessicles, pruritis & associated w/global headache. Rx Benadryl & hydrocortisone cream. Headache, pruritus urticaria
This spontaneous report as received from a healthcare worker refers to a 16 year old female patient with none medical history and none drug allergies. On 24-JAN-2012 the patient was vaccinated with GARDASIL (Lot# 1277Y and exp date 29-JUN-2012) 0.5 ml, intramuscular, once. No other co-suspects were reported. No concomitant therapy was reported. The healthcare worker reported that the patient fainted at home after receiving the first dose of GARDASIL, approximately in January 2012. The patient also developed headaches and dizziness few days after vaccination, so the patient could not go to school for 2-3 days. Treatment was not given. Lab tests were not performed. The outcome of the patient fainted at home after receiving the first dose of GARDASIL, the patient also developed headaches and dizziness a few days after the vaccination and the patient also developed headaches and dizziness a few days after the vaccination was reported as recovered/resolved. Additional information is not expected.
Possible febrile seizure. Episode pallor and went limp. Seemed dazed with roving eyes. Episode lasted 15 minutes. Evaluated at Medical Center. Initial elevated WBC's, but resumed to normal. CXR was normal and BP ok.
At 10:00: Fussy, crying at site (13:30) redness, swelling, hot to touch, painful when pt moved. Copies of OV records for date of these immunizations and subsequent AE are received. PMD's assessment was that of adverse reaction to Hib, swollen, injected and tender w/ no induration, almost constant shrill crying. At this return visit, approx 5 hrs post immunizations, child's rectal temp was 98.9. He had been given Tylenol at 11:30 AM, approx 90 min post immunizations. The well child visit that same morning notes a healthy 6 mos. old recovered from cough and recently off Reglan and Zantac. Temp was 99.3 F at that time.  Hospital records for the 23 hr stay note a diagnosis of immunization reaction and mild dehydration for this event. There was no temp elevation during this stay and the extremities had good ROM and there were no significant findings at the injection site. Neuro exam was normal.
Subject reports that she received the anthrax vaccine in late Oct/early Nov of 2001. Beginning in Nov 2001, she reportedly was in an out of the ER and base clinic repeatedly for feeling like she had the flu and migraines. She reportedly was admitted to the hospital the first week in December for a series of tests. While hospitalized she reportedly became disoriented and left side of body became numb. Final diagnosis of viral encephalitis and stroke. She reportedly began to experience times where she would pass out, and was further diagnosed with neurocardiovascular syncope. She was medically discharged from the military in January 2003 with a 10% disability. Since that time she has been upgraded to 40% disability. Subject reportedly still experiences passing out, having partial seizures, and chostochondritis intermittently, along with ongoing arthritis in joints. Subject reportedly has been in a wheelchair since July 2006. Diagnosed with "ataxia celiac disease". Has received physical therapy since July 2006 with some improvement in strength. Continues to follow up with neurologist, cardiologist and GI specialists. Other problems reportedly include SOB and asthma and tumor in leg for which she is scheduled to have surgery in 2 weeks.
This spontaneous report as received from a pharmacy technician concerning a currently 14 months old child. Gender was not reported. Medical history and concurrent conditions were not reported. On 28-MAR-2014, the patient was vaccinated with VARIVAX lot #J009165; expiration date: 24-JUL-2015 (dose, strength and route were not reported). Secondary and concomitant therapies were not reported. Patient was vaccinated with VARIVAX that was exposed to 43.1 degrees F for 29 hours on 03-MAR-2014. This is one of several reports from the same reporter. Additional information has been requested.
This spontaneous report as received from a consumer refers to his wife. The female patient was vaccinated with a dose of ZOSTAVAX on an unknown date. No other co-suspects were reported. No concomitant medications were reported. The patient had some redness after she received the ZOSTAVAX vaccine. The outcome of redness was unknown. This is one of several reports received from the same reporter. Additional information is not expected.
States 1 week before 2nd vaccine she had right axillary lymph node swelling, which has continued to now, 1 week after 2nd vaccine developed shortness of breath, and hematuria. Continues shortness of breath. Hematuria lasted 2 weeks. Seen by PCP on 3/4/21 & in ER on 4/8/21.
Headache, nausea, body aches, chills, temperature 99F starting around 6pm on the day of vaccination (I received the vaccine at 7:30am). This lasted all night and was resolved by 1pm the following day.
Information has been received from a certified nurse midwife concerning an 18 year old female who on an unspecified date was vaccinated with dose unspecified of Gardasil. On an unspecified date, the patient fainted in the physician's office waiting room after receiving the vaccination. The patient hit her head on the counter and sustained unspecified head trauma. The patient was hospitalized. At the time of reporting, the outcome was unknown. Additional information has been requested.
My doctor says he knows of 10-12 other patients that have vestibular neuritis after a COVID-19 shot; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VESTIBULAR NEURONITIS (My doctor says he knows of 10-12 other patients that have vestibular neuritis after a COVID-19 shot) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VESTIBULAR NEURONITIS (My doctor says he knows of 10-12 other patients that have vestibular neuritis after a COVID-19 shot). At the time of the report, VESTIBULAR NEURONITIS (My doctor says he knows of 10-12 other patients that have vestibular neuritis after a COVID-19 shot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported.  Treatment information not reported.   Most recent FOLLOW-UP information incorporated above includes: On 26-Jul-2021: Follow up received contains no new information.
1.  PT hospitalized 4 months prior to service for Guillain Barre. 2.  Denied Previous hospitalizations on entrance physical.  3.  Denied Previous diagnosis of Guillain Barre on Anthrax questionnaire.  4.  Recieved anthrax vaccine 5 Mar 2009.  5.  Developed signs and symptoms of Guillain Barre.  Currently worsening, hospitalized, being transported.  3/19/09 MR received. Pt presented March 10 with c/o generalized muscle weakness-especially in the legs, numbness primarily paresthesias in the L hand and increased fatigue. PE (+) for areflexia. Admitted with possible dx AIDP, CIDP vs ?.  Per report, transferred for eval. 4/6/09 Additional records received from transfer facility. Eval for weakness, dyspnea and fatigue s/p anthrax vax on 3/5/09. Still reporting an area of altered sensation on the R lower thorax as well as occ shock-like sensations with foot contact to floor and fatigue. Pt reports becoming winded more easily and has not been able to train as hard as usual. PE (+) for sensory abnormalities noted in flank area.  Strength WNL. Absent reflexes in ankle and crossed adductor.   Assessment:  Muscle Weakness of uncertain etiology. Possible subclinical GBS. Returned home for outpt f/u. 4/28/09 Additional records received for DOS 3/12-16/09 with D/C DX:  Likely Conversion Disorder. Hx as above. improved by 3/16/09.
The evening of the vaccine Maddison had slightly labored breathing, pins and needles feelings in feet and hands. Fever, body aches. The morning after while taking their temperature, Maddison said she couldn't see anything then fell into my arms. Her pupils quickly dilated, she made gutteral sounds while shaking slightly then lost consciousness. I couldn't see her breathing for about 15 seconds and she was confused when she came to. She couldn't hear, see or speak during the episode. We took her to the emergency room where a chest xray and ekg came back clear.